Valuation: Interpace Biosciences, Inc.

Market Cap 41.55M 36.51M 33.85M 31.13M 58.81M 3.97B 60.08M 404M 158M 1.95B 156M 153M 6.75B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 40.23M 35.35M 32.77M 30.14M 56.94M 3.85B 58.17M 391M 153M 1.89B 151M 148M 6.53B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
14.74%
Yield 2024 *
-
Yield 2025 -
1 day-8.54%
1 week-7.98%
Current month-7.98%
1 month-6.25%
3 months-34.78%
6 months+24.48%
Current year+21.93%
1 week 1.47
Extreme 1.47
1.65
1 month 1.47
Extreme 1.47
1.8
Current year 1.03
Extreme 1.03
2.4
1 year 0.76
Extreme 0.76
2.4
3 years 0.44
Extreme 0.4433
3.54
5 years 0.44
Extreme 0.4433
10.5
10 years 0.44
Extreme 0.4433
198
Manager TitleAgeSince
Chief Executive Officer 63 2020-11-30
Director of Finance/CFO 34 2023-04-20
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 78 2016-06-20
Director/Board Member 73 2015-12-31
Director/Board Member 64 2020-01-21
Date Insider Type Main position Quantity % Market Cap.
Jan. 19
1315 Capital LLC
ConversionCompany 9,405,941 212.3938%
Jan. 19
Ampersand Management LLC
ConversionCompany 13,861,386 313.0013%
24-01-31Free

Chief Financial Officer

10,000 0.2314%
Change 5-day change 1-year change 3-year change Capi.($)
-8.54%-7.98%+86.52%-32.43% 45.43M
+1.09%-2.30%+70.10%+433.82% 38.66B
-0.05%-3.59%+10.84%+29.85% 22.7B
-1.46%-1.51%-23.11%-39.58% 7.3B
-3.49%-7.91%+14.11%+104.49% 5.16B
+1.91%+4.82%+17.90%+44.90% 2.97B
-2.73%-5.42%-22.66%+800.56% 1.95B
-1.17%0.00%+33.47%-19.89% 1.84B
0.00%-6.93%+94.35%-16.80% 1.84B
+4.87%+3.19%+25.58%+4.06% 1.75B
Average -0.96%-0.51%+30.71%+130.90% 8.42B
Weighted average by Cap. +0.22%-2.62%+37.44%+229.57%

Financials

2024 2025
Net sales 46.93M 41.23M 38.23M 35.16M 66.41M 4.49B 67.85M 456M 178M 2.2B 176M 172M 7.62B 38.73M 34.03M 31.55M 29.01M 54.81M 3.7B 56M 376M 147M 1.82B 145M 142M 6.29B
Net income 6.7M 5.89M 5.46M 5.02M 9.49M 641M 9.69M 65.09M 25.49M 315M 25.16M 24.61M 1.09B 24.58M 21.59M 20.02M 18.41M 34.78M 2.35B 35.53M 239M 93.45M 1.15B 92.27M 90.25M 3.99B
Net Debt 4.4M 3.86M 3.58M 3.29M 6.22M 420M 6.35M 42.68M 16.71M 207M 16.5M 16.14M 714M -1.32M -1.16M -1.08M -990K -1.87M -126M -1.91M -12.84M -5.03M -62.12M -4.96M -4.86M -215M
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
26-07-13 $1.500 -8.54% 3,221
26-07-10 $1.640 +0.11% 4,640
26-07-09 $1.638 +0.81% 673
26-07-08 $1.625 -1.22% 550
26-07-07 $1.645 -0.30% 1,281

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXG Stock